Rheumatology 2006;45:746–750 doi:10.1093/rheumatology/kei279
Advance Access publication 10 January 2006

Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of *MEFV* mutations

H. J. Lachmann, B. Şengül[1], T. U. Yavuzşen[1], D. R. Booth, S. E. Booth, A. Bybee, J. R. Gallimore, M. Soytürk[1], S. Akar[1], M. Tunca[1] and P. N. Hawkins

***Objective*. To prospectively monitor inflammatory activity over a prolonged period in a cohort of Turkish patients with FMF, their healthy relatives and healthy controls and to relate this to their *MEFV* genotypes.**
***Methods*. 43 patients with FMF and 75 of their asymptomatic relatives underwent fortnightly assessments and venesection for measurement of CRP and SAA over 5 months. 50 unrelated healthy population matched controls were also studied. MEFV genotyping was performed on all participants and comparisons were made between the different groups.**
***Results*. Paired *MEFV* mutations were detected in 84% of FMF patients and single mutations in 12%. Substantial acute phase reactivity was seen among the patients with FMF during attacks (median SAA 693 mg/l, CRP 115 mg/l). Between attacks there was also some inflammatory activity (median SAA 6 mg/l, CRP 4 mg/l). Among healthy controls 16% were heterozygotes for *MEFV* mutations and 4% had two mutations. As expected there was a substantial carrier rate among healthy relatives with mutations detected in almost 92%. Asymptomatic *MEFV* heterozygotes had elevated acute phase proteins compared to wild type subjects.**
***Conclusion*. Substantial sub-clinical inflammation occurs widely and over prolonged periods in patients with FMF, indicating that the relatively infrequent clinically overt attacks represent the 'tip of the iceberg' in this disorder. Both basal and peak acute phase protein concentrations were greater in *MEFV* heterozygotes than in wild-type controls, regardless of mutation demonstrating a 'pro-inflammatory' phenotype among FMF carriers. Upregulation of the acute phase response among carriers of FMF may augment their innate host response and contribute to better resistance to infection.**

KEY WORDS: Familial Mediterranean fever, *MEFV*, Heterozygote, Carrier state, Acute phase response, CRP, SAA, Turkey.

Familial Mediterranean fever (FMF) is an autosomal recessive autoinflammatory disease characterized by recurrent, self-limiting attacks of fever, and serositis including, in some individuals, arthritis or rash [1, 2]. Most patients present in childhood or as young adults with attacks that commonly last for less than 3 days and typically occur every few weeks or months [3]. FMF occurs worldwide and predominantly affects the populations arising from the Eastern Mediterranean basin, particularly the non-Ashkenazi Jews, Armenians, Turks, Cypriots and Levantine Arabs [4–8]. FMF is caused by various mutations in the gene *MEFV* [9, 10], which encodes a protein named pyrin/marenostrin and is chiefly expressed in neutrophils [11]. Variant forms of pyrin/marenostrin are thought to allow inappropriate triggering of neutrophil activation, giving rise to the apparently unprovoked short-lived bursts of systemic inflammation that are evident clinically in FMF [12, 13]. *MEFV* genotyping has contributed greatly to knowledge of FMF, but the diagnosis remains predominantly clinical [2, 14] since mutations are not always penetrant and cannot always be identified on both alleles [7, 15].

Clinical attacks of FMF are accompanied by a number of laboratory abnormalities, including a low-grade neutrophilia and an acute-phase plasma protein response [16], but the most responsive and dynamic acute-phase markers, serum amyloid A protein (SAA) and C-reactive protein (CRP), have not previously been investigated in depth. SAA is the circulating precursor of AA amyloid fibrils [17, 18], and sustained long-term elevation of SAA concentration is the only known prerequisite for the development of AA amyloidosis [19]. The behaviour of SAA over time is of interest in patients with FMF because the natural history of this disease includes a remarkably high incidence of AA amyloidosis. Prior to the discovery in 1972 that colchicine prophylaxis decreases clinical attacks and the risk of amyloid in most patients, up to 60% of patients with FMF died of amyloidosis [20–22], but even recently it has been reported in 12.9% of patients in a large series from Turkey [23]. Individuals can present with amyloidosis before developing symptoms of FMF, described as phenotype II [24], which, along with the observation that most patients with FMF are symptomatic for less than 40 days per year [25], had led to suggestions that the genesis of amyloid in this disorder may differ from that in other chronic inflammatory diseases [20, 26, 27].

In order to further characterize the relationship between specific mutations and the inflammatory activity that occurs in FMF, we performed a prospective study in which the acute-phase proteins SAA and CRP were monitored fortnightly over a prolonged period

Centre for Amyloidosis and Acute Phase Proteins, Royal Free and University College Medical School, London, UK and [1]Department of Internal Medicine, Dokuz Eylül University School of Medicine, Izmir, Turkey.

Submitted 25 August 2005; revised version accepted 25 November 2005.

Correspondence to: H. J. Lachmann, National Amyloidosis Centre, Department of Medicine, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK. E-mail: h.lachmann@medsch.ucl.ac.uk

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Downloaded from https://academic.oup.com/rheumatology/article-abstract/45/6/746/1785056 by guest on 05 March 2020

(5 months) in Turkish patients with well characterized FMF, their first-degree relatives and healthy population-matched controls.

Patients and methods

The subjects were 168 ethnic Turks living in the western coastal region of Turkey, in an area served by the Dokuz Eylül University School of Medicine, Izmir. The group comprised 43 patients who fulfilled clinical diagnostic criteria for FMF and 75 of their asymptomatic first-degree relatives from 35 families, and 50 unrelated healthy population-matched controls. FMF in all of the patients had been well characterized and they had all been prescribed prophylactic colchicine at doses of 1–1.5 mg depending on body weight. The protocol for the patients and relatives comprised fortnightly home assessments and venesection for estimation of CRP and SAA for 5 months, and keeping diaries throughout the study period to record symptoms referable to FMF and any intercurrent illnesses. The 50 controls were all overtly healthy adults who each provided three serum blood samples at fortnightly intervals. The protocol included *MEFV* genotyping in all participants. The study was approved by the Dokuz Eylül University School of Medicine ethical committee and all participants provided informed consent before entering the study.

Measurement of CRP and serum amyloid A protein

All analyses were performed at the end of the study period on separated serum, which had been stored at –30°C. Under these conditions the proteins are very stable [28].

Serum CRP concentration was determined using a high-sensitivity (hs) automated microparticle-enhanced latex turbidimetric immunoassay (Cobas Mira; Roche Diagnostics). The lower limit of detection was 0.2 mg/l; the interassay coefficient of variation (CV) was 4.2% at 4 mg/l and 6.3% at 1 mg/l. SAA concentration was measured by latex nephelometry (BNII auto-analyser; Dade Behring, Marburg, Germany) [29].The lower limit of detection was 0.7 mg/l; the interassay CV was 2.6% at 15 mg/l and 3.7% at 80 mg/l. Both assays were standardized with the appropriate WHO standards [30, 31].

MEFV genotyping

Genomic DNA was isolated by a rapid method from frozen whole blood taken into ethylenediamine tetraacetate (EDTA) and solubilized in 10 mM Tris, pH 7.5/1 mM EDTA [32]. The coding regions of the *MEFV* gene were amplified by the polymerase chain reaction (PCR) using *Taq* polymerase (Amplitaq; Perkin Elmer Cetus) and sequenced using BigDye® Terminator sequencing chemistry and an ABI 310 sequencing machine as previously described [10].

Statistical analysis

The median and maximum hs-CRP and SAA values were determined for each participant and the results were compared in patients with FMF, their healthy relatives and controls. Within the FMF group, values for hs-CRP and SAA were compared during and between clinical attacks. Comparisons were also made between different *MEFV* genotypes, among both FMF patients and asymptomatic heterozygotes. The results were analysed using non-parametric statistics, including the Mann–Whitney U-test.

Results

DNA analysis was unsuccessful in one of the healthy controls. No *MEFV* mutations were identified in exons 2, 3, 5 or 10 among 39 (80%) of the remaining 49 individuals. However, two of these healthy subjects were found to have pairs of FMF-associated mutations, encoding the variants V726A/E148Q and M694V/E148Q, respectively; these have been reported separately [15]. Eight others (16%) were simple heterozygotes (Table 1).

Among the 43 patients with FMF, paired *MEFV* mutations were identified in 36 cases (84%). Thirty of these had two mutations in exon 10, including six who were homozygous for M694V, which is reported to be associated with a severe phenotype, and six had an exon 10 mutation in conjunction with the E148Q variant (Table 1). A single mutation was detected in five patients (12%), and no mutations were found in two cases (5%). One of these patients without identified mutations had no evidence

Table 1. *MEFV* genotyping in patients with familial Mediterranean fever, their asymptomatic first-degree relatives and healthy Turkish controls

MEFV mutation		Clinical FMF ($n=43$)		Asymptomatic relatives ($n=73$)		Healthy controls ($n=49$)	
Exon 10	Exon 2	No.	%	No.	%	No.	%
V726A	E148Q					1	2%
V726A	E148V	2	4.7%	2	12.3%		
M680I	E148Q			1	1.4%		
M680I		2	4.7%	7	9.6%		
M680I/M680I		2	4.7%				
M680I/M694V		4	9.3%	1	1.4%		
M680I/V726A		4	9.3%				
M680I/R761H		2	4.7%				
M694V	E148Q	6	14%	2	2.7%	1	2%
M694V		2	4.7%	30	41.1%	2	4.1%
M694V/M694V		6	14%	1	1.4%		
M694V/V726A		7	16.3%				
M694V/R761H		2	4.7%	1	1.4%		
K695R						1	2%
V726A		1	2.3%	9	12.3%	1	2%
V726A/V726A		1	2.3%	1	1.4%		
V726A/R761H	E148V	2	4.7%				
R761H				3	4.1%		
	E148Q			9	12.3%	4	8.2%
No mutation identified		2	4.7%	6	8.2%	39	79.6%
Single mutation		5	11.6%	58	79.4%	8	16.3%
Two or more mutations		36	83.7%	9	12.3%	2	4.1%
Two mutations in exon 10		30	69.8%	4	5.5%		

Downloaded from https://academic.oup.com/rheumatology/article-abstract/45/6/746/1785056 by guest on 05 March 2020

of significant inflammatory activity and no clinical attacks during the study period (hs-CRP, median 1.1 mg/l, maximum 2.6 mg/l); the other had levels of inflammation compatible with FMF patients with confirmed mutations (hs-CRP, median 16.1 mg/l, maximum 100.2 mg/l)

The allele frequency of *MEFV* mutations among the 73 asymptomatic parents or siblings of patients with FMF was 0.58. Fifty-eight (80%) of these subjects were heterozygotes, and, despite their lack of symptoms, nine (12%) individuals had paired mutations (Table 1).

Serial measurements of the acute-phase reactants SAA and hs-CRP in the 38 asymptomatic individuals who were *MEFV* wild-type gave values that were within the range reported in healthy control populations, in which 90% values of are less than 3 mg/l. The median SAA value was 2.2. mg/l and the median hs-CRP value was 1.3 mg/l. Occasional spikes of acute-phase activity were recorded in these individuals but only in the presence of reported intercurrent illness, such as upper respiratory tract infections. The maximum recorded values for SAA (277 mg/l) and hs-CRP (24.4 mg/l) occurred during a self-reported attack of 'influenza'.

By contrast, substantial acute-phase activity was evident among the patients with FMF. Of the 43 patients, 14 (33%) had two or three FMF attacks during the study period, a further 14 had a single attack and 15 patients reported no FMF symptoms, although seven of these individuals reported episodes of mild 'flu'-like symptoms that they attributed to viral illnesses. Both SAA and hs-CRP were massively elevated during all reported clinical attacks of FMF in all patients, with median values of 693 (range 140–1330) mg/l and 115 (range 26–296) mg/l, respectively. SAA and hs-CRP were also both elevated compared with the healthy control group even when these patients were free of FMF symptoms [median SAA 6.0 (range 0.7–1230) mg/l; median hs-CRP 4.0 (range 2.7–262) mg/l]. Even when the patients were asymptomatic, only 29% of SAA measurements in the FMF patients were less than 3 mg/l, i.e. within the normal range; 65% were less than 10 mg/l and 13% of SAA values exceeded 50 mg/l. Markedly elevated SAA values in eight individuals who reported no FMF or other symptoms throughout the study are shown in Fig. 1. Median SAA and hs-CRP values were significantly higher ($P < 0.01$) in the six pyrin M694V homozygotes compared with the other 11 patients, who had two non-M694V variants, consistent with clinical studies that have reported that homozygosity for pyrin M694V is associated with a more severe disease phenotype. Median and maximum SAA and hs-CRP values were significantly higher ($P < 0.05$) in the 30 patients who had two exon 10 mutations compared with the 11 patients who had only one exon 10 mutation (Table 2), suggesting a gene dose effect.




FIG. 1. Fortnightly SAA measurements, plotted on a logarithmic scale, in the eight FMF patients who remained completely without symptoms throughout the study period, showing substantial subclinical inflammatory activity. Thirteen per cent of all SAA values were greater than 50 mg/l. The median SAA value is indicated for each patient. Three patients were M694V/E148Q, including patient 7, who had very little evidence of inflammation. The other five patients all had two exon 10 mutations.

Among 66 asymptomatic relatives and healthy controls who were heterozygous for a single *MEFV* mutation, i.e. FMF carriers, median and peak values of SAA and hs-CRP were modestly but significantly higher than among subjects in whom no mutations were identified: E148Q heterozygotes had a higher median and maximum hs-CRP and maximum SAA; carriers of M694V had significantly higher basal hs-CRP and maximum SAA and hs-CRP; M680I heterozygotes had a very similar picture, whereas healthy individuals with V726A had significantly higher peak SAA values (Table 3).

Discussion

This study has shown that substantial subclinical inflammation occurs widely and over prolonged periods in patients with FMF, indicating that the relatively infrequent clinically overt attacks represent the tip of the iceberg in this disorder. Although measurements of hs-CRP and SAA are well established to be the most sensitive and dynamic indicators of the acute-phase response, the magnitude of their elevation in active FMF, especially SAA, far exceeds values seen in most other chronic inflammatory diseases. The up-regulation of SAA and CRP production during health and intercurrent illness observed here over a prolonged time course in characterized *MEFV* heterozygotes confirms and extends previous observations on the phenotype of FMF carriers [33].

The degree and periodic pattern with which SAA was elevated in patients with FMF is significant for several reasons. Firstly, it may help to point towards this diagnosis, since very few disorders are associated with repeatedly high SAA values of more than 1000 mg/l [34]. Secondly, the SAA concentration was always very significantly elevated during symptomatic attacks of FMF, and therefore a lack of intense acute-phase response during symptoms of abdominal pain, pleurisy and fever, etc., in an individual known to have FMF should suggest an alternative aetiology. Thirdly, the amount of acute-phase SAA production in asymptomatic patients with FMF is sufficient to account for their susceptibility to the development of AA amyloidosis, solving the enigma of why such an apparently intermittent disorder or, in the case of phenotype II FMF, an entirely subclinical process should lead to this life-threatening complication.

Substantial clinical experience has shown that regular prophylactic treatment with daily colchicine, at doses between 500 μg and 2.5 mg a day, inhibits attacks of FMF in two-thirds of patients [35], and prevents the development of AA amyloidosis in the vast majority of cases [36]. This treatment had been prescribed to all patients studied here, but the remarkable degree and intensity of acute-phase activity led us to question the participants' compliance with the drug. Our suspicion was supported by experience that we have acquired though monitoring disease activity with monthly SAA measurements among FMF patients who have been under long-term follow-up in our centre in London, in whom we have observed SAA values of less than 10 mg/l on most occasions in most patients who assert that they are compliant with colchicine. On subsequent questioning after the present study had been completed, about half of the patients reported here admitted using colchicine either erratically or otherwise inappropriately. Since there is no risk of AA amyloidosis developing in individuals who do not have abnormal overproduction of SAA, frequent SAA measurements in patients with FMF may help to reinforce drug compliance, as well as providing objective evaluation of response and reassurance to the attending physician.

Downloaded from https://academic.oup.com/rheumatology/article-abstract/45/6/746/1785056 by guest on 05 March 2020

TABLE 2. Grouped results for patients with clinical FMF according to *MEFV* genotype, showing the median values and range of each parameter of the acute-phase response during the study period

MEFV mutation	Median hs-CRP (mg/l)	Median SAA (mg/l)	Maximum hs-CRP (mg/l)	Maximum SAA (mg/l)	Median number of attacks per patient
Single exon 10 and an exon 2 mutation ($n=11$)	2.7[b] (1.1–11.3)	2.4 (1.0–18.2)	9.4[a] (1.6–82)	7.9[b] (2.0–644)	1 (0–2)
Two exon 10 mutations ($n=30$)	4.9[b,c] (1.2–36.6)	7.0[b] (1.0–162)	41.8[b,c] (1.8–262.3)	152[b,c] (1.7–1330)	1 (0–3)
M694V and another exon 10 mutation ($n=13$)	3.0[b,c] (1.2–11.3)	4.6[a] (1.0–23.2)	48.9[b,d] (1.8–129.7)	91.3[b,d] (1.7–1230)	1 (0–2)
M694V homozygotes ($n=6$)	16.0[b,d,e] (11.4–37)	31.3[b,d,e] (15.1–162)	51.0[b,d] (26.6–152)	279[b,d,e] (136–1030)	1 (0–3)

The Mann–Whitney U-test was performed on the acute-phase parameters of each individual. Comparisons were made between groups: [a]$P<0.05$, [b]$P<0.01$ compared with wild-type controls; [c]$P<0.05$, [d]$P<0.01$ compared with asymptomatic *MEFV* heterozygotes; [e]$P<0.05$ comparing the all other FMF patient genotypes with M694V homozygotes.

TABLE 3. Summary of grouped results for wild-type and healthy *MEFV* heterozygotes showing the median values and range of each parameter of the acute-phase response

MEFV mutation	Median hs-CRP (mg/l)	Median SAA (mg/l)	Maximum hs-CRP (mg/l)	Maximum SAA (mg/l)
Wild-type ($n=38$)	1.2 (0.2–6.3)	2.2 (0.7–17)	2.2 (0.2–24.4)	3.5 (1.0–277)
E148Q ($n=11$)	2.0[b] (0.4–9.0)	4.2[a] (1.3–8.7)	3.4 (0.4–26.8)	11.0[a] (1.4–187.0)
M694V ($n=32$)	1.5[b] (0.6–5.2)	2.7 (1.1–13.2)	4.4[b] (1.3–38.1)	11.1[b] (1.6–536)
V726A ($n=10$)	1.3 (0.3–6.2)	2.0 (1.2–5.9)	4.4 (0.8–15.8)	15.4[a] (3.4–49.9)
M680I ($n=7$)	2.0[b] (1.3–3.1)	4.7[b] (1.8–5.9)	4.8[a] (3.0–26.5)	10.5[b] (4.1–509)

[a]$P<0.05$, [b]$P<0.01$ for Mann–Whitney analysis comparing the wild-type controls and *MEFV* heterozygotes, performed on the acute-phase parameters of each individual.

Other notable findings in this study included the results of *MEFV* genotyping. The sequencing method used was relatively comprehensive but would not detect intronic mutations or indeed variant *MEFV* regulatory proteins. We identified pairs of mutations in more than 80% of patients with FMF, and single mutations in all but 5% of the remainder. The frequency of mutated *MEFV* alleles in the healthy control group was 22%, and pairs of mutations known to be associated with FMF were present in two of these individuals and in 12% of the patients' apparently healthy relatives. In contrast, no mutations were identified in two FMF patients, emphasizing the limitations of genotyping in the diagnosis of this disorder and the need to use clinical criteria to make the diagnosis.

We have previously demonstrated that obligate carriers of FMF had increased levels of acute-phase reactants [37], and the combination of *MEFV* genotyping coupled with high-sensitivity acute-phase response measurements over several months reported here enabled us to confirm and further elucidate the pro-inflammatory phenotype among characterized heterozygous FMF carriers. Both basal and peak acute-phase protein concentrations were greater in *MEFV* heterozygotes than in wild-type controls, regardless of mutation. All endothermic animals mount an acute-phase response, suggesting that it may have survival value. Indeed, in an experimental mouse model, induction of the acute-phase response by a single sterile inflammatory stimulus markedly enhances resistance to otherwise lethal pyogenic bacterial infection [38]. Up-regulation of the acute-phase response among carriers of FMF may thus have benefited their innate host response and contributed to better resistance to infection, suggesting a hypothesis that the pyrin heterozygote state may have conferred a survival advantage during periods when early mortality from infectious disease was the major selection pressure. These advantages conferred by an up-regulated inflammatory response may be balanced in later life by a predisposition to atherosclerosis. However, despite widespread evidence that CRP is a moderate predictor of coronary heart disease [39], there is little published on the risk of heart disease in FMF. The only published paper suggests that colchicine-treated patients have no increased risk compared with the general population [40], and nothing is known yet on the incidence of cardiac disease among asymptomatic *MEFV* heterozygotes.

Acknowledgements

This work was supported in part by grants to P.N.H. from the Medical Research Council (UK) and The Wellcome Trust, and by NHS Research and Development Funds.

The authors have declared no conflicts of interest.

References

1. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967;43:227–53.
2. Livneh A, Langevitz P, Zemer D *et al*. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997;40:1879–85.
3. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet 1998;351:659–64.
4. Orbach H, Ben-Chetrit E. Familial Mediterranean fever – a review and update. Minerva Med 2001;92:421–30.
5. Deltas CC, Mean R, Rossou E *et al*. Familial Mediterranean fever (FMF) mutations occur frequently in the Greek-Cypriot population of Cyprus. Genet Test 2002;6:15–21.
6. Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations. Eur J Hum Genet 2001;9:473–83.
7. Gershoni-Baruch R, Shinawi M, Leah K, Badarnah K, Brik R. Familial Mediterranean fever: prevalence, penetrance and genetic drift. Eur J Hum Genet 2001;9:634–7.
8. Cattan D, Dervichian M, Thomas M, Dode C, Touitou I. MEFV mutations and phenotype-genotype correlations in North African Jews and Armenians with familial Mediterranean fever. Isr Med Assoc J 2001;3:803–4.
9. The French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997;17:25–31.
10. The French FMF Consortium. Ancient missense mutations in a new member of the *RoRet* gene family are likely to cause familial Mediterranean fever. Cell 1997;90:797–807.

Downloaded from https://academic.oup.com/rheumatology/article-abstract/45/6/746/1785056 by guest on 05 March 2020

11. Centola M, Wood G, Frucht DM *et al*. The gene for familial Mediterranean fever, *MEFV*, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 2000;95:3223–31.
12. Richards N, Schaner P, Diaz A *et al*. Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. J Biol Chem 2001;276:39320–9.
13. Ozen S, Uckan D, Baskin E *et al*. Increased neutrophil apoptosis during attacks of familial Mediterranean fever. Clin Exp Rheumatol 2001;19:S68–71.
14. Grateau G, Pêcheux C, Cazeneuve C *et al*. Clinical versus genetic diagnosis of familial Mediterranean fever. Q J Med 2000;93:223–9.
15. Tunca M, Akar S, Hawkins PN *et al*. The significance of paired MEFV mutations in individuals without symptoms of familial Mediterranean fever. Eur J Hum Genet 2002;10:786–9.
16. Korkmaz C, Ozdogan H, Kasapcopur O, Yazici H. Acute phase response in familial Mediterranean fever. Ann Rheum Dis 2002; 61:79–81.
17. Pras M, Schubert M, Zucker-Franklin D, Rimon A, Franklin EC. The characterisation of soluble amyloid prepared in water. J Clin Invest 1968;47:924–33.
18. Rosenthal CJ, Franklin EC, Frangione B, Greenspan J. Isolation and characterization of SAA amyloid related protein from human serum. J Immunol 1976;116:1415–8.
19. de Beer FC, Mallya RK, Fagan EA, Lanham JG, Hughes GRV, Pepys MB. Serum amyloid A protein (SAA) concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982;ii:231–4.
20. Gafni J, Ravid M, Sohar E. The role of amyloidosis in familial Mediterranean fever. A population study. Isr J Med 1968;4:995–9.
21. Ozdemir AI, Sokmen C. Familial Mediterranean fever among the Turkish people. Am J Gastroenterol 1969;51:311–6.
22. Ozer FL, Kaplaman E, Zileli S. Familial Mediterranean fever in Turkey. A report of twenty cases. Am J Med 1971;50:336–9.
23. Turkish FMF study Group. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 2005;84:1–11.
24. Blum A, Gafni J, Sohar E, Shibolet S, Heller S. Amyloidosis as the sole manifestation of familial Mediterranean fever (FMF). Further evidence of its genetic nature. Ann Intern Med 1962;57:795–9.
25. Pras M. Familial Mediterranean fever: from the clinical syndrome to the cloning of the pyrin gene. [Editorial.] Scand J Rheumatol 1998;27:92–7.
26. Heller H, Sohar E, Gafni J, Heller J. Amyloidosis in familial Mediterranean fever: an independent genetically determined character. Arch Intern Med 1961;107:539–50.
27. Saatci U, Ozen S, Ozdemir S *et al*. Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr 1997;156: 619–23.
28. Myers GL, Rifai N, Tracy RP *et al*. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Report from the laboratory science discussion group. Circulation 2004;110:e545–9.
29. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998;35:745–53.
30. WHO Expert Committee on Biological Standardization. WHO Technical Report Series 760. Geneva: World Health Organization, 1987:21–2.
31. Poole S, Walker D, Gaines Das RE, Gallimore JR, Pepys MB. The first international standard for serum amyloid A protein (SAA). Evaluation in an international collaborative study. J Immunol Methods 1998;214:1–10.
32. Talmud P, Tybjaerg-Hansen A, Bhatnagar D *et al*. Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolaemia. Atherosclerosis 1991;89:137–41.
33. Ozen S, Bakkaloglu A, Yilmaz E *et al*. Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation? J Rheumatol 2003;30:2014–8.
34. Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 1999;37:381–8.
35. Zemer D, Livneh A, Danon YL, Pras M, Sohar E. Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 1991;34:973–7.
36. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of amyloidosis of familial Mediterranean fever. N Engl J Med 1986;314:1001–5.
37. Tunca M, Kirkali G, Soyturk M, Akar S, Pepys MB, Hawkins PN. Acute phase response and evolution of familial Mediterranean fever. Lancet 1999;353:1415.
38. Noursadeghi M, Cohen J. The acute phase response and enhancing resistance to bacterial infection. In: Vincent J-L, ed. Update in intensive care and emergency medicine. Berlin: Springer, 1999:116–39.
39. Danesh J, Wheeler JG, Hirschfield GM *et al*. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387–97.
40. Langevitz P, Livneh A, Neumann L, Buskila D, Shemer J, Amolshy D, Pras M. Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J 2001;3:9–12.

Downloaded from https://academic.oup.com/rheumatology/article-abstract/45/6/746/1785056 by guest on 05 March 2020